The difference between avatrombopag and eltrombopag/eltrombopag

Eltrombopag/Eltrombopag and Avatrombopag are both thrombopoietin receptor agonists (TPO-RA). Their main function is to increase the number of platelets in the blood by stimulating platelet production in the bone marrow. Although the two drugs have similar mechanisms of action, there are some differences in their use, indications, and side effects.

Eltrombopag is mainly used to treat adult patients with chronic idiopathic thrombocytopenic purpura (ITP), especially those who have poor response to treatments such as corticosteroids and immunoglobulins. It can increase platelet counts and reduce or prevent bleeding. Eltrombopag is the first oral peptide thrombopoietin receptor agonist approved to treat adult patients with chronic ITP. When using eltrombopag, the starting dose is usually 25 mg daily, and it is recommended to take it on an empty stomach (one hour before or two hours after meals). Side effects of eltrombopag may include nausea, vomiting, muscle pain, paresthesia, cataracts, and indigestion.

Avatrombopag is the world's first oral thrombopoietin receptor agonist approved by the US Food and Drug Administration (FDA) for the treatment of thrombocytopenia associated with chronic liver disease (CLD). It is indicated primarily for adult patients with chronic liver disease-related thrombocytopenia scheduled for elective diagnostic procedures or surgery to reduce the risk of procedure-related bleeding. In addition to CLD-related thrombocytopenia, avatrombopag also has a presence in the fields of tumor chemotherapy-induced thrombocytopenia (CIT) and immune thrombocytopenia (ITP). Side effects of avatrombopag may include headache, cough, diarrhea, and vomiting.